PURPOSE: To validate the increase in intraocular pressure (IOP) caused by soluble adenylyl cyclase (sAC) inhibitors and determine reasons behind variation in IOP measurements performed by tonometry. METHODS: C57BL/6J mice were administered DMSO solubilized sAC inhibitors (KH7 or LRE-1) by intraperitoneal injection. Two hours post-treatment, mice were anesthetized with avertin or ketamine/xylazine/acepromazine (KXA). IOP was measured by a rebound tonometer or direct cannulation of the anterior chamber. Spectral-domain optical coherence tomography was used to measure anterior chamber depth and corneal thickness in live mice. Outflow facility was measured in perfused, enucleated mouse eyes. RESULTS: Compared with DMSO controls, KH7 treatment caused an increased IOP in avertin- and KXA-anesthetized mice when measured by direct cannulation [avertin: 14.4 ± 2.1 mmHg vs. 11.1 ± 1.0 mmHg (P = 0.003); KXA: 14.4 ± 1.0 mmHg vs. 11.3 ± 0.8 mmHg (P < 0.001)] and tonometry [avertin: 10.8 ± 1.4 mmHg vs. 7.4 ± 0.6 mmHg (P < 0.001); KXA: 11.9 ± 0.9 mmHg vs. 10.3 ± 1.7 mmHg (P = 0.283)]. However, treatment with KH7 in nonanesthetized mice showed a significant decrease in IOP measured by tonometry and compared with DMSO-treated animals [13.1 ± 2.6 mmHg vs. 15.6 ± 0.5 mmHg (P = 0.003)]. Both KH7- and DMSO-treated groups anesthetized with avertin showed increased corneal thickness, whereas KH7-treated mice anesthetized with KXA exhibited a shallower anterior chamber compared with untreated mice. KH7 decreased outflow facility by 85.1% in nonanesthetized, enucleated eyes (P < 0.003). CONCLUSIONS: Systemically administered DMSO and anesthesia have significant effects on anterior chamber characteristics, resulting in altered IOP readings measured by tonometry. In the presence of DMSO and anesthesia, tonometry IOP readings should be confirmed with direct cannulation.
PURPOSE: To validate the increase in intraocular pressure (IOP) caused by soluble adenylyl cyclase (sAC) inhibitors and determine reasons behind variation in IOP measurements performed by tonometry. METHODS: C57BL/6J mice were administered DMSO solubilized sAC inhibitors (KH7 or LRE-1) by intraperitoneal injection. Two hours post-treatment, mice were anesthetized with avertin or ketamine/xylazine/acepromazine (KXA). IOP was measured by a rebound tonometer or direct cannulation of the anterior chamber. Spectral-domain optical coherence tomography was used to measure anterior chamber depth and corneal thickness in live mice. Outflow facility was measured in perfused, enucleated mouse eyes. RESULTS: Compared with DMSO controls, KH7 treatment caused an increased IOP in avertin- and KXA-anesthetized mice when measured by direct cannulation [avertin: 14.4 ± 2.1 mmHg vs. 11.1 ± 1.0 mmHg (P = 0.003); KXA: 14.4 ± 1.0 mmHg vs. 11.3 ± 0.8 mmHg (P < 0.001)] and tonometry [avertin: 10.8 ± 1.4 mmHg vs. 7.4 ± 0.6 mmHg (P < 0.001); KXA: 11.9 ± 0.9 mmHg vs. 10.3 ± 1.7 mmHg (P = 0.283)]. However, treatment with KH7 in nonanesthetized mice showed a significant decrease in IOP measured by tonometry and compared with DMSO-treated animals [13.1 ± 2.6 mmHg vs. 15.6 ± 0.5 mmHg (P = 0.003)]. Both KH7- and DMSO-treated groups anesthetized with avertin showed increased corneal thickness, whereas KH7-treated mice anesthetized with KXA exhibited a shallower anterior chamber compared with untreated mice. KH7 decreased outflow facility by 85.1% in nonanesthetized, enucleated eyes (P < 0.003). CONCLUSIONS: Systemically administered DMSO and anesthesia have significant effects on anterior chamber characteristics, resulting in altered IOP readings measured by tonometry. In the presence of DMSO and anesthesia, tonometry IOP readings should be confirmed with direct cannulation.
Authors: Jay S Pepose; Susan K Feigenbaum; Mujtaba A Qazi; Jeffrey P Sanderson; Cynthia J Roberts Journal: Am J Ophthalmol Date: 2006-10-20 Impact factor: 5.258
Authors: Jose M Martinez-de-la-Casa; Julian Garcia-Feijoo; Eva Vico; Ana Fernandez-Vidal; Jose M Benitez del Castillo; Mohamed Wasfi; J Garcia-Sanchez Journal: Ophthalmology Date: 2006-09-25 Impact factor: 12.079
Authors: Herbert A Reitsamer; Jeffrey W Kiel; Joseph M Harrison; Nancy L Ransom; Stuart J McKinnon Journal: Exp Eye Res Date: 2004-04 Impact factor: 3.467
Authors: Uttio Roy Chowdhury; Cindy K Bahler; Bradley H Holman; Peter I Dosa; Michael P Fautsch Journal: PLoS One Date: 2015-11-04 Impact factor: 3.240
Authors: Fukutaro Mano; Jarel K Gandhi; Raphael Pereira da Silva; Aline Do Amaral Silva; Lucas Iezzi; Raymond Iezzi; Jose S Pulido; Alan D Marmorstein Journal: Transl Vis Sci Technol Date: 2022-04-01 Impact factor: 3.048
Authors: Uttio Roy Chowdhury; Rachel A Kudgus; Bradley H Holman; Tommy A Rinkoski; Cheryl R Hann; Cindy K Bahler; Eric McCloud; Susan E Appt; Joel M Reid; Peter I Dosa; Michael P Fautsch Journal: J Ocul Pharmacol Ther Date: 2021-03-30 Impact factor: 2.850
Authors: Thomas Rossetti; Jacob Ferreira; Lubna Ghanem; Hannes Buck; Clemens Steegborn; Robert W Myers; Peter T Meinke; Lonny R Levin; Jochen Buck Journal: Front Physiol Date: 2022-09-28 Impact factor: 4.755